A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
Robert I. Haddad(Georgetown University), Benjamin M. Robinson, Luis Paz‐Ares(Hospital Universitario 12 De Octubre), A Krebs, James R. Vasselli(The University of Texas MD Anderson Cancer Center)
Cited by 37
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k